Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 4, 2014, Pages 682-693

  Trigonis, Ioannis ^a   Koh, Pek Keng ^b   Taylor, Ben ^c   Tamal, Mahbubunnabi ^a   Ryder, David ^c   Earl, Mark ^c   Anton Rodriguez, Jose ^a   Haslett, Kate ^b,c   Young, Helen ^d   Faivre Finn, Corinne ^b,c   Blackhall, Fiona ^b,c   Jackson, Alan ^a   Asselin, Marie Claude ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Early response monitoring; Non small cell lung cancer; Radiotherapy

Indexed keywords

3' FLUOROTHYMIDINE F 18; CARBOPLATIN; CISPLATIN; GEMCITABINE; PEMETREXED; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG UPTAKE; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PROSPECTIVE STUDY; RADIATION RESPONSE; REPRODUCIBILITY; STANDARDIZED UPTAKE VALUE; TREATMENT RESPONSE; TUMOR VOLUME; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC USE; LUNG NEOPLASMS; MIDDLE AGED; SCINTISCANNING;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DIDEOXYNUCLEOSIDES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 84897023854     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2632-3     Document Type: Article

References (34)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43. (Pubitemid 33586866)
2. Price A. Lung cancer 5: state of the art radiotherapy for lung cancer. Thorax 2003;58:447-52. (Pubitemid 36560950)
3. Bayman NA, Blackhall F, Jain P, Lee L, Thatcher N, Faivre-Finn C. Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. Clin Lung Cancer 2008;9:92-101. (Pubitemid 351631920)
4. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90.
5. Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009;15:406-20.
6. Seddon BM, Workman P. The role of functional and molecular imaging in cancer drug discovery and development. Br J Radiol 2003;76(76 Spec No 2):S128-38.
7. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 2006;33 Suppl 1:27-37.
8. Riesterer O, Milas L, Ang KK. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol 2007;25:4075-83. (Pubitemid 47495867)
9. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008;14:5967-76.
10. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011;11:239-53.
11. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med 2008;49 Suppl 2:64S-80.
12. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-23. (Pubitemid 35340704)
13. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46:274-82. (Pubitemid 43073435)
14. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003;44:1426-31. (Pubitemid 39663355)
15. Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, et al. Correlation of 18F-FLT and 18F-FDG uptake on PETwith Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:1610-6. (Pubitemid 47476919)
16. Brockenbrough JS, Souquet T, Morihara JK, Stern JE, Hawes SE, Rasey JS, et al. Tumor 3′-deoxy-3′-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PETstudies in lung tumors. J Nucl Med 2011;52:1181-8.
17. Sugiyama M, Sakahara H, Sato K, Harada N, Fukumoto D, Kakiuchi T, et al. Evaluation of 3′-deoxy-3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004;45:1754-8. (Pubitemid 47618487)
18. Yang YJ, Ryu JS, Kim SY, Oh SJ, Im KC, Lee H, et al. Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 2006;33:412-9.
19. Pan MH, Huang SC, Liao YP, Schaue D, Wang CC, Stout DB, et al. FLT-PET imaging of radiation responses in murine tumors. Mol Imaging Biol 2008;10:325-34.
20. Murayama C, Harada N, Kakiuchi T, Fukumoto D, Kamijo A, Kawaguchi AT, et al. Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice. J Nucl Med 2009;50:290-5.
21. Everitt S, Hicks RJ, Ball D, Kron T, Schneider-Kolsky M, Walter T, et al. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;75:1098-104.
22. Vera P, Bohn P, Edet-Sanson A, Salles A, Hapdey S, Gardin I, et al. Simultaneous positron emission tomography (PET) assessment of metabolism with (18)F-fluoro-2-deoxy-d-glucose (FDG), proliferation with (18)F-fluoro-thymidine (FLT), and hypoxia with (18)fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol 2011;98:109-16.
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
24. Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F] fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 2000;243:843-6. (Pubitemid 30462551)
25. Levitt SH. Technical basis of radiation therapy: practical clinical applications. 4th rev. ed. Berlin: Springer; 2006.
26. Hatt M, Cheze-Le Rest C, Aboagye EO, Kenny LM, Rosso L, Turkheimer FE, et al. Reproducibility of 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET tumor volume measurements. J Nucl Med 2010;51:1368-76.
27. Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, van Tinteren H, Boellaard R. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med 2010;51:1870-77.
28. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339-47. (Pubitemid 47312585)
29. de Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, et al. Reproducibility of quantitative 18F-3′-deoxy-3′- fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 2009;36:389-95.
30. Shields AF, Lawhorn-Crews JM, Briston DA, Zalzala S, Gadgeel S, Douglas KA, et al. Analysis and reproducibility of 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4463-8.
31. de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, et al. Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med 2012;53:701-8.
32. Dewalle-Vignion AS, Yeni N, Petyt G, Verscheure L, Huglo D, Béron A, et al. Evaluation of PET volume segmentation methods: comparisons with expert manual delineations. Nucl Med Commun 2012;33:34-42.
33. Hamill JJ, Bosmans G, Dekker A. Respiratory-gated CT as a tool for the simulation of breathing artifacts in PET and PET/CT. Med Phys 2008;35:576-85. (Pubitemid 351190877)
34. El Naqa I, Low DA, Bradley JD, Vicic M, Deasy JO. Deblurring of breathing motion artifacts in thoracic PET images by deconvolution methods. Med Phys 2006;33:3587-600. (Pubitemid 44505085)